229 related articles for article (PubMed ID: 21632869)
1. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
Kennedy PC; Zhu R; Huang T; Tomsig JL; Mathews TP; David M; Peyruchaud O; Macdonald TL; Lynch KR
J Pharmacol Exp Ther; 2011 Sep; 338(3):879-89. PubMed ID: 21632869
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
Zhu R; Snyder AH; Kharel Y; Schaffter L; Sun Q; Kennedy PC; Lynch KR; Macdonald TL
J Med Chem; 2007 Dec; 50(25):6428-35. PubMed ID: 17994678
[TBL] [Abstract][Full Text] [Related]
4. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.
Gonzalez-Cabrera PJ; Hla T; Rosen H
J Biol Chem; 2007 Mar; 282(10):7254-64. PubMed ID: 17218309
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Sanna MG; Liao J; Jo E; Alfonso C; Ahn MY; Peterson MS; Webb B; Lefebvre S; Chun J; Gray N; Rosen H
J Biol Chem; 2004 Apr; 279(14):13839-48. PubMed ID: 14732717
[TBL] [Abstract][Full Text] [Related]
6. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.
Camp SM; Bittman R; Chiang ET; Moreno-Vinasco L; Mirzapoiazova T; Sammani S; Lu X; Sun C; Harbeck M; Roe M; Natarajan V; Garcia JG; Dudek SM
J Pharmacol Exp Ther; 2009 Oct; 331(1):54-64. PubMed ID: 19592667
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.
Foss FW; Mathews TP; Kharel Y; Kennedy PC; Snyder AH; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem; 2009 Aug; 17(16):6123-36. PubMed ID: 19632123
[TBL] [Abstract][Full Text] [Related]
8. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
9. Lymphopenia induced by a novel selective S1P(1) antagonist structurally unrelated to S1P.
Fujii Y; Ohtake H; Ono N; Hara T; Sakurai T; Takahashi S; Takayama T; Fukasawa Y; Shiozawa F; Tsukahara N; Hirayama T; Igarashi Y; Goitsuka R
Biochim Biophys Acta; 2012 Apr; 1821(4):600-6. PubMed ID: 22265714
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate analogs as receptor antagonists.
Davis MD; Clemens JJ; Macdonald TL; Lynch KR
J Biol Chem; 2005 Mar; 280(11):9833-41. PubMed ID: 15590668
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
12. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
Trifilieff A; Fozard JR
J Pharmacol Exp Ther; 2012 Aug; 342(2):399-406. PubMed ID: 22570366
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.
Diab KJ; Adamowicz JJ; Kamocki K; Rush NI; Garrison J; Gu Y; Schweitzer KS; Skobeleva A; Rajashekhar G; Hubbard WC; Berdyshev EV; Petrache I
Am J Respir Crit Care Med; 2010 Feb; 181(4):344-52. PubMed ID: 19965812
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.
Hofmann U; Hu K; Walter F; Burkard N; Ertl G; Bauersachs J; Ritter O; Frantz S; Bonz A
Br J Pharmacol; 2010 Jul; 160(5):1243-51. PubMed ID: 20590616
[TBL] [Abstract][Full Text] [Related]
17. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
18. Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays.
Riddy DM; Stamp C; Sykes DA; Charlton SJ; Dowling MR
Br J Pharmacol; 2012 Oct; 167(4):868-80. PubMed ID: 22577868
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
Murakami A; Takasugi H; Ohnuma S; Koide Y; Sakurai A; Takeda S; Hasegawa T; Sasamori J; Konno T; Hayashi K; Watanabe Y; Mori K; Sato Y; Takahashi A; Mochizuki N; Takakura N
Mol Pharmacol; 2010 Apr; 77(4):704-13. PubMed ID: 20097776
[TBL] [Abstract][Full Text] [Related]
20. FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury.
Wang L; Sammani S; Moreno-Vinasco L; Letsiou E; Wang T; Camp SM; Bittman R; Garcia JG; Dudek SM
Crit Care Med; 2014 Mar; 42(3):e189-99. PubMed ID: 24335440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
